Provesica successor Ario revives ion channel candidate for cough
By Nuala Moran
Monday, December 30, 2013
LONDON – A phoenix has arisen from the ashes of Provesica Ltd., raising £1.9 million (US$3.1 million) to repurpose the failed company’s only asset, XEN-D0501, as a treatment for chronic cough.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.